Introduction
============

PTXs are a superfamily of evolutionarily conserved proteins that are characterized by the presence of a structural motif termed the PTX domain. Short PTXs, C-reactive protein, and serum amyloid P component are acute-phase proteins in man and mouse, respectively, produced mainly by the liver in response to inflammatory stimuli, such as IL-6 \[[@B1]\]. PTX3 was the first long PTX described as an IL-1β-inducible gene in endothelial cells. A variety of cell types produces PTX3 in response to proinflammatory stimuli; these include endothelial cells, smooth muscle cells, adipocytes, fibroblasts, mononuclear phagocytes, DC, and granulosa cells \[[@B1]\]. Recently, we found that PTX3 is stored in neutrophil-specific granules and undergoes release in response to microbial recognition and inflammatory signals \[[@B2]\]. PTX3 binds selected ligands, such as C1q, and specific microorganisms and microbial moieties, thereby initiating an innate immune response, possibly through complement activation \[[@B3]--[@B5]\]. Studies in vivo with PTX3-deficient mice have revealed that PTX3 plays a number of nonredundant roles in innate resistance to selected pathogens \[[@B6]\] and during inflammation \[[@B4], [@B7]\]. In humans, increased levels of PTX3 are found in different infectious diseases \[[@B8], [@B9]\], in autoimmune disorders \[[@B10], [@B11]\], and in inflammatory conditions, reflecting, in particular, the involvement of the vascular bed \[[@B12], [@B13]\].

TSG-6, also known as TNFAIP6, is a 35-kDa-secreted protein, comprised almost entirely of a Link module and a CUB_C domain, where the former binds to a wide range of ECM components including HA, chondroitin-4-sulfate, and aggrecan (reviewed in refs. \[[@B14], [@B15]\]), and the latter has been shown recently to bind fibronectin \[[@B16]\]. TSG-6 is up-regulated rapidly in response to proinflammatory cytokines (e.g., IL-1 and TNF-α) and various growth factors, and it is produced by a wide range of cell types, including chondrocytes, synoviocytes, and smooth muscle cells. High levels of TSG-6 are found in the synovial fluids of patients with RA and osteoarthritis and also in sera of individuals with bacterial sepsis and other inflammatory diseases \[[@B17], [@B18]\]. PTX3 and TSG-6 are expressed by granulosa cells and cumulus cells following the luteinizing hormone surge and are associated with the ECM surrounding the oocyte during the periovulatory period. Moreover, PTX3 binds to TSG-6 and to IαI and is believed to form a multimolecular complex that might support HA cross-linking \[[@B19], [@B20]\]. These three proteins have crucial roles in the structural organization of cumulus oophorus ECM, which is essential for in vivo fertilization. Indeed, the deficiency of any one of these three molecules causes defective cumulus oophorus expansion and female subfertility or sterility as a result of defective in vivo fertilization \[[@B19], [@B21]--[@B23]\]. *PTX3* and *TSG-6* transcripts were also found to be induced in decidual stromal cells by the trophoblast in in vitro systems that mimic the alteration of the local immune environment induced by the trophoblast in the process of embryo implantation \[[@B24], [@B25]\]; however, their role in this context has not been elucidated yet.

TSG-6 has been implicated in the process of HA cross-linking, which might potentially occur through a number of different mechanisms, first, by acting as cofactor and catalyst in the covalent transfer of the HC of IαI onto HA (thereby forming HC•HA complexes, which are more aggregated than free HA \[[@B26], [@B27]\]), and second, more speculatively, by forming multimolecular complexes with PTX3 that act as foci for the attachment of multiple HA chains via the Link module of TSG-6 \[[@B19], [@B28]\]. It has been shown recently that HC • HA complexes are likely to associate directly with PTX3, leading to an alternative method of cross-linking \[[@B20]\]. Besides its role in HA cross-linking, TSG-6 has anti-inflammatory and chondroprotective roles in arthritis \[[@B29]--[@B31]\], which might relate to its abilities to potentiate the anti-plasmin and anti-tissue kallicrein activities of IαI \[[@B31]--[@B35]\] and to inhibit neutrophil migration \[[@B36]--[@B38]\].

The aim of this study was to analyze the expression and coregulation of TSG-6 and PTX3 in different cell types and in particular, in myelomonocytic cells, which are the major producers of PTX3 \[[@B39]\]. Here, we show that myelomonocytic cells and MoDC are a major source of TSG-6 and that PTX3 and TSG-6 are coregulated under most of the conditions tested. The coordinated expression of PTX3 and TSG-6 may play a role in ECM remodeling at sites of inflammation.

MATERIALS AND METHODS
=====================

Reagents
--------

For cell culture, we used the following reagents: RPMI-1640 medium (Biochrom, Berlin, Germany), L-glutamine (Biochrom), and aseptically collected FCS (Hyclone Laboratories, Logan, UT, USA). hIL-13 was a gift from Dr. Adrian Minty (Sanofi Elf Bio Recherches, Labege, France), and rhGM-CSF was a gift from Novartis (Milan, Italy). rhM-CSF was from Peprotech (London, UK). LPS from *Escherichia coli* strain 055:B5 was obtained from Sigma-Aldrich (St. Louis, MO, USA). rhIL-1β was from Dompè (L\'Aquila, Italy). rhIFN-γ and IL-4 were purchased from Peprotech. rhIL-10 was kindly provided by Prof. Giorgio Trinchieri (Schering Plough, Kenilworth, NJ, USA). Actinomycin D (Sigma-Aldrich) was used at 1 μg/ml. All reagents contained \<0.125 endotoxin unit/ml as checked by the Limulus amoebocyte lysate assay (BioWhittaker, Inc., Walkersville, MD, USA).

Cell culture
------------

Monocytes were isolated from fresh buffy coats of healthy donors (Centro Trasfusionale Ospedale Niguarda, Milan, Italy) using Ficoll (Biochrom) and Percoll (Amersham, Uppsala, Sweden). Nonadherent cells were discarded, and the purified monocytes were incubated with different stimuli as indicated. To obtain MoDC, purified monocytes were cultured for 6 days at 10^6^ cells/ml with 50 ng/ml GM-CSF and 20 ng/ml IL-13 \[[@B40]\]. To obtain macrophages, monocytes were cultured at 2 × 10^6^ cell/ml in Petriperm dishes (Petriperm Hydrophobic, Heraeus Instruments GmbH, Munich, Germany) for 5 days with 40 ng/ml M-CSF \[[@B39]\]. Circulating human lymphocytes and PMN were obtained from peripheral blood of healthy donors. Cells were separated by Percoll gradient after centrifugation as described \[[@B2]\]. Purity, determined by FACS analysis on forward-scatter/side-scatter parameters, was routinely \>98%. T lymphocytes were stimulated for 48 h with 100 U/ml PHA. NK cells were obtained through Ficoll gradient, followed by monocyte depletion and discontinuous Percoll gradient. Dr. Angela Santoni (University "La Sapienza," Rome, Italy) provided primary cells prepared in this way, as well as NK 925 and YT6 NK cell lines. Total and large B cells were prepared from tonsils as described in ref. \[[@B41]\]. HUVEC were obtained as described in ref. \[[@B42]\] and cultured with LPS (10 ng/ml) or IL-1β (20 ng/ml). HDMEC were obtained from Dr. Moshe Arditi (Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, USA) \[[@B43]\]. The human lung fibroblast cell line W138 was obtained from American Type Culture Collection (Manassas, VA, USA). Dr. Mario Luppi (University of Modena and Reggio Emilia, Italy) provided A549, a human lung carcinoma cell line, and BEAS-2B, a nontumorogenic bronchial epithelial cell line. Cells were cultured in RPMI-1640 medium containing 10% (v/v) FCS.

To study *PTX3* and *TSG-6* expression, cells were plated at 10^6^ cell/ml, 3 ml/well and incubated for the times indicated with the following reagents: LPS (100, 10, or 1 ng/ml), IFN-γ (5000 or 500 U/ml), IL-13, IL-10, or IL-4 (20 ng/ml for all). LPS was added to relevant cultures 30 min after exposure to other stimuli. Three to four donors were tested for each condition.

Northern blot analysis
----------------------

Total RNA was extracted using TRIzol, according to the manufacturer\'s instructions (Invitrogen, Life Technologies, Carlsbad, CA, USA), blotted, and hybridized as described \[[@B39]\]. The probes *hPTX3*, a full-length hPTX3 cDNA, and *hTSG-6*, a cDNA corresponding to the Link module of hTSG-6 (Link_TSG6) \[[@B44]\], were labeled with (α-^32^P) dCTP (3000 Ci/mmol) (Amersham, Buckinghamshire, UK) using the Megaprime DNA labeling system (Amersham, Buckinghamshire, UK).

Detection of TSG-6 and PTX3 by ELISA and Western blot
-----------------------------------------------------

To determine the presence of TSG-6 or PTX3 in supernatants, cells were cultured in RPMI-1640 medium containing 3% (v/v) FCS (10^6^/ml DC and 5×10^6^/ml PMN). To detect TSG-6 by ELISA, 96-well Maxisorp plates (Nunc, Denmark) were coated overnight at room temperature with 125 ng/well rat anti-hTSG-6 mAb (A38) \[[@B45]\] in 20 mM Na~2~CO~3~, pH 9.6. Plates were washed three times with PBS/0.05% (v/v) Tween-20 after this and all subsequent steps. Nonspecific sites were blocked with 0.25% (w/v) BSA in PBS/0.05% (v/v) Tween-20 (blocking buffer) for 1 h at 37°C. Wells were then incubated for 2 h at room temperature with dilutions of rhTSG-6 \[[@B46]\] in blocking buffer (50 μl/well) or with DC or PMN supernatants (100 μl/well), followed by 10 ng/well biotinylated goat anti-hTSG-6 antibody (R&D Systems, Minneapolis, MN, USA) in blocking buffer for 90 min at room temperature. Bound antibody was detected by incubation for 30 min with ExtrAvidin alkaline phosphatase (Sigma-Aldrich), diluted 1:10,000 in blocking buffer and then with Sigma Fast p-nitrophenyl phosphate. Absorbance values at 405 nm were read after 45 min.

For Western blot analysis, DC culture supernatants (1 ml) were mixed with 10 μl Strataclean resin (Stratagene, La Jolla, CA, USA) for 30 s at room temperature. The resin was collected by centrifugation, and proteins were fractionated on 10% (w/v) Tris/Tricine/SDS-polyacrylamide gels following reduction with 5% (v/v) β-ME in SDS protein sample buffer (5 min at 100°C) and then transferred onto polyvinylidene difluoride membrane (Amersham). Aliquots, 50 ng-purified rhTSG-6, were run as controls. TSG-6 was detected on Western blots using biotinylated R-C21 antibody \[1:2000 dilution; raised against residues 135--150 of murine TSG-6 and kindly provided by Prof. Katalin Mikecz (Chicago, IL, USA\], followed by HRP-conjugated strepavidin (GE Healthcare, Waukesha, WI, USA) and ECL Advance detection reagents (GE Healthcare).

ELISA for PTX3 was performed as described \[[@B2]\].

Detection of TSG-6 and PTX3 by confocal microscopy
--------------------------------------------------

Neutrophils were freshly isolated or cultured in the presence of 100 ng/ml LPS for 30 min or 4 h and seeded on precoated (poly-L-lysine) glass coverslips or cytospun, fixed with 4% (v/v) PFA and permeabilized for 5 min with 0.3% (v/v) Triton (Sigma-Aldrich) and 0.1% (v/v) SDS in PBS, pH 7.4, before incubation for 1 h at 4°C with 10% (v/v) normal goat serum (Sigma-Aldrich) and glycine 0.1% (v/v) in PBS. Specimens were incubated with 1 μg/ml affinity-purified polyclonal RAH-1 \[[@B47]\] or purified preimmune rabbit serum as control, followed by incubation with Alexa Fluor 488-conjugated anti-rabbit IgG (1:2000, Molecular Probes, Eugene, OR, USA). Cells were postfixed with 1% (v/v) PFA for 5 min at room temperature, followed by incubation with biotin-conjugated, affinity-purified rabbit IgG against hPTX3 (0.5 μg/ml) \[[@B2]\], mouse anti-lactoferrin mAb (1 mg/ml; HyCult Biotechnology, Uden, The Netherlands), or IgG isotype control mAb for 1 h at 4°C. After each step, cells were washed with 0.2% (v/v) BSA and 0.05% (v/v) Tween-20 in PBS (pH 7.4). Sections were mounted with FluorSave™ reagent (Calbiochem, San Diego, CA, USA) and analyzed with an Olympus Fluoview FV1000 laser-scanning confocal microscope. Images (1024×1024 pixels) were acquired with a 100× 1.4 NA Plan-Apochromat oil immersion objective (Olympus, Hamburg, Germany).

Immunohistochemistry
--------------------

The expression patterns of PTX3 and TSG-6 were studied by immunohistochemistry in colon tissues from two patients with inflammatory bowel disease. Samples were collected and frozen in liquid nitrogen. Sections (9 μm) were cut and mounted on poly-L-lysine-coated slides. After fixation with acetone/chloroform for 3 min, sections were incubated for 2 h with the following antibodies: affinity-purified rabbit IgG against hPTX3 (250 ng/ml) \[[@B2]\] and polyclonal RAH-1 (7 μg/ml) \[[@B47]\]. Binding to target protein was determined using the nonbiotin peroxidase detection system with 3,3′ diaminobenzidine freebase as chromogen. The primary antibody was omitted from negative controls. TSG-6-producing cells were identified using cytological and morphological parameters and by performing double-immunohistochemical reactions on consecutive slides with polyclonal rabbit anti-hTSG-6 along with monoclonal mouse anti-hCD15 (Dako, Denmark, to detect PMN), CD68 (Dako, to detect macrophages), or CD31 (Dako, to detect endothelial cells). TSG-6 was visualized in red (with Alexa Fluor 594-conjugated goat anti-rabbit as secondary antibody, Molecular Probes), and the anti-PMN, -macrophages, and -endothelial cells were developed in green (using Alexa Fluor 488-conjugated goat anti-mouse as secondary antibody, Invitrogen-Molecular Probes). Nuclei were stained with 4′,6-diamidino-2-phenylindole (Invitrogen-Molecular Probes). Slides were mounted with FluorSave (Calbiochem) and analyzed by immunofluorescence microscopy.

RESULTS
=======

Expression of TSG-6 and PTX3 mRNA in human cells
------------------------------------------------

To study *TSG-6* and *PTX3* mRNA expression in human cells, we performed Northern blot analysis of total RNA using radiolabeled *hTSG-6* and *hPTX3* cDNAs as probes. When comparing *TSG-6* and *PTX3* expression under identical conditions, blots were first hybridized with the *TSG-6* probe and then, after stripping, with the *PTX3* probe.

Analysis of material from unstimulated cell lines (**[Fig. 1](#F1){ref-type="fig"}, A** and **B**) generally revealed little or no expression of *TSG-6* or *PTX3* mRNA. *TSG-6* was detectable only in the bronchial epithelial cell line BEAS-2B ([Fig. 1](#F1){ref-type="fig"}A), and *PTX3* was evident in endothelial cells (HUVEC and HDMEC) and fibroblasts as well as BEAS-2B cells. TNF-α-treated fibroblasts and IL-1β-treated HUVECs showed up-regulation of *PTX3* and to a lesser extent, *TSG-6* mRNA, and LPS induced the production of *PTX3* but not *TSG-6* in HUVECs.

![*TSG-6* and *PTX3* expression in different human cell lines and leukocyte subpopulations.\
(A) Total RNA was extracted using TRIzol from bronchial epithelial cells (A549), transformed bronchial epithelial cells (BEAS-2B), fibroblasts (W138), and endothelial cells (HUVEC, HDMEC), cultured in the presence of LPS, TNF-α, or IL-1β where specified and analyzed by Northern blotting. Total RNA (10 μg) was run in each lane, and the lower panels show the ethidium bromide-stained membranes to confirm mRNA transfer. Blots were first hybridized with a human Link_TSG6 cDNA probe (*hTSG-6*) and then, after stripping, with *hPTX3*. (B) Total RNA was extracted from freshly isolated human monocytes, cultured macrophages, MoDC, PMN, B and T lymphocytes, and NK cells. Where indicated, cells were incubated with LPS (10 ng/ml) for 4 h or in the case of lymphocytes, with PHA (100 U/ml) for 48 h. Northern blot analysis with *hTSG-6* and *hPTX3* probes was performed as described for A.](zgb0070948670001){#F1}

To compare *TSG-6* and *PTX3* expression in leukocyte populations, we isolated fresh human monocytes, T lymphocytes, NK cells, and PMN from the peripheral blood of healthy donors. Macrophages and MoDC were differentiated from monocytes as described above, and B cells were prepared from tonsils. As shown in [Figure 1](#F1){ref-type="fig"}B, under resting conditions, there was no evidence of *TSG-6* transcript in monocytes, macrophages, circulating B cells, large B cells from tonsils, or NK cells (freshly isolated or cultured cell lines). In contrast, freshly isolated PMN exhibited a strong signal for *TSG-6* mRNA, which almost disappeared after 20 h in culture (see **[Fig. 2](#F2){ref-type="fig"}**). T lymphocytes and to a lesser extent, immature MoDC also expressed low levels of *TSG-6* mRNA ([Fig. 1](#F1){ref-type="fig"}B). None of the cell types tested expressed *PTX3* mRNA in resting conditions ([Fig. 1](#F1){ref-type="fig"}B).

![Kinetics of *PTX3* and *TSG-6* expression in human monocytes and PMN.\
Monocytes and PMN were isolated from buffy coats and incubated with LPS (100 ng/ml) for 4 h or 20 h. RNA was extracted, and the expression of *TSG-6* was analyzed by Northern blot analysis. Membranes were subsequently stripped and hybridized with the *PTX3* probe. The lower panels show ethidium bromide-stained membranes.](zgb0070948670002){#F2}

The stimulation of lymphocytes with PHA induced *TSG-6* expression but had no effect on *PTX3* ([Fig. 1](#F1){ref-type="fig"}B). In contrast, *TSG-6* and *PTX3* transcripts were induced in monocytes, macrophages, and MoDC following the engagement of TLR4 by LPS (see [Figs. 1](#F1){ref-type="fig"}B and [2](#F2){ref-type="fig"}). In MoDC, which are the major producers of PTX3 upon TLR engagement \[[@B39]\], *PTX3* and *TSG-6* were induced by LPS in a dose-dependent manner with expression being detectable from a dose of 1 ng/ml (see below). Analysis of the kinetics of *TSG-6* and *PTX3* expression in monocytes after LPS stimulation (**[Fig. 2](#F2){ref-type="fig"}**) revealed that the induction of both mRNAs was rapid and transient, peaking at 4 h and being strongly reduced after 20 h of stimulation. LPS also caused up-regulation of *TSG-6* expression in PMN after 4 h of incubation, which persisted after 20 h ([Fig. 2](#F2){ref-type="fig"}); *PTX3* message was not detected in PMN in response to any of the stimuli tested, as expected \[[@B2]\], and was not studied further.

Regulation of TSG-6 and PTX3 expression by pro- and anti-inflammatory stimuli
-----------------------------------------------------------------------------

We next analyzed whether LPS-induced *TSG-6* and *PTX3* mRNA levels in leukocytes were comodulated by a series of pro- and anti-inflammatory cytokines.

Treatment with IL-4 alone did not modify *TSG-6* or *PTX3* expression in monocytes (not shown), MoDC, or PMN (**[Fig. 3](#F3){ref-type="fig"}**). However, IL-4 was seen to inhibit LPS-induced expression of *TSG-6* and *PTX3* in MoDC ([Fig. 3](#F3){ref-type="fig"}A) and less efficiently, in monocytes (not shown). In MoDC, this inhibitory effect of IL-4 was particularly strong in the case of *PTX3*, which was barely detectable when the high or low doses of LPS (10 and 1 ng/ml, respectively) were used. *TSG-6* was strongly induced in MoDC even with the lower dose of LPS, and the inhibitory effect of IL-4 was substantially less than that seen for *PTX3* ([Fig. 3](#F3){ref-type="fig"}A). In PMN incubated for 4 h with LPS and IL-4, the *TSG-6* mRNA level was only reduced slightly compared with that in cells treated with LPS alone ([Fig. 3](#F3){ref-type="fig"}B). However, after 20 h incubation, IL-4-mediated inhibition of this LPS activity was pronounced. PMN were also treated with IL-13, which inhibited LPS-induced *TSG-6* message expression, although to a lesser extent than IL-4 ([Fig. 3](#F3){ref-type="fig"}B). These, along with previous results for PTX3 \[[@B40]\], suggest that *TSG-6* and *PTX3* are coregulated by the anti-inflammatory cytokines IL-4 and IL-13 in leukocytes.

![Comparison of *TSG-6* and *PTX3* expression in human leukocytes stimulated with pro- and anti-inflammatory stimuli.\
(A) MoDC were differentiated from monocytes and incubated for 4 h with the stimuli indicated; two different concentrations of LPS were used (1 and 10 ng/ml), where this was added to the cultures after 30 min preincubation with IL-10, IL-4 (20 ng/ml), or IFN-γ (5000 U/ml). After total mRNA extraction, *TSG-6* and *PTX3* expression was determined by Northern blot analysis. The lower panels show the ethidium bromide-stained membranes. The figure shows PTX3 and TSG-6 expression in MoDC in one donor out of the three tested, where these all gave similar results. (B) hPMN were incubated for 4 h or 20 h with LPS (100 ng/ml), alone or in combination with IFN-γ (5000 U/ml), IL-10, IL-4, or IL-13 (20 ng/ml), where the latter was added to cultures 30 min prior to LPS. Ctrl, Control.](zgb0070948670003){#F3}

It has been demonstrated that in apparent contrast to its general anti-inflammatory role, IL-10 alone slightly induces *PTX3* mRNA expression in monocytes and DC; furthermore, it synergizes with LPS in up-regulating *PTX3* transcript and protein levels \[[@B40], [@B48]\]. IL-10 was not able to induce *TSG-6* expression in monocytes (not shown) or MoDC ([Fig. 3](#F3){ref-type="fig"}A) or PMN ([Fig. 3](#F3){ref-type="fig"}B) and actually exerted a slight negative effect on LPS-induced *TSG-6* transcription in monocytes (not shown), MoDC, and PMN ([Fig. 3](#F3){ref-type="fig"}, A and B).

IFN-γ is a negative regulator of TLR-mediated induction of PTX3 transcription and protein release \[[@B49]\]. Therefore, it is not surprising that IFN-γ alone has no effect on *PTX3* mRNA production and that it down-regulates LPS-induced transcription in MoDC ([Fig. 3](#F3){ref-type="fig"}A). Interestingly, LPS-induced *TSG-6* expression was variably modulated by IFN-γ, depending on the cell type analyzed; we observed some induction of *TSG-6* message by IFN-γ alone in monocytes (not shown) and to a greater extent in PMN after 20 h of incubation and some enhancement of LPS-induced transcription in PMN ([Fig. 3](#F3){ref-type="fig"}B). In macrophages (not shown) and MoDC ([Fig. 3](#F3){ref-type="fig"}A), IFN-γ had no effect on *TSG-6* transcription, alone or in combination with LPS.

Release of TSG-6 by MoDC and PMN
--------------------------------

MoDC have been studied extensively in relation to the production of PTX3 upon TLR engagement and the regulation of this effect by pro- and anti-inflammatory cytokines \[[@B39], [@B40]\]. As illustrated in **[Figure 4](#F4){ref-type="fig"}A**, which shows one out of three experiments performed, we measured TSG-6 levels in MoDC supernatants, cultured for 24 h with LPS as an inflammatory stimulus in the absence or presence of IL-4, IL-10, or IFN-γ as modulators. The secretion of TSG-6 into the supernatants of LPS-treated MoDC was confirmed by Western blot analysis ([Fig. 4](#F4){ref-type="fig"}B); in addition to free TSG-6 protein (∼35 kDa), a species of ∼120 kDa, which is likely to correspond with a covalent complex of IαI HC with TSG-6 (i.e., TSG-6•HC), was also detected as a result of the presence of bovine serum in the culture medium \[[@B27], [@B50], [@B51]\]. In agreement with the mRNA data ([Fig. 3](#F3){ref-type="fig"}A), LPS-induced TSG-6 release was not modified by treatment with IFN-γ. IL-4 and IL-10 had small but significant inhibitory effects on LPS-induced TSG-6 expression. IFN-γ, IL-4, or IL-10 alone did not induce protein secretion.

![Secretion of TSG-6 by DC and neutrophils.\
(A) TSG-6 was detected in DC culture supernatants by sandwich ELISA, using A38 as capture antibody and biotinylated anti-TSG-6 (R&D Systems) for detection. Values from one donor out of three tested are shown. Values are plotted as ng/ml (*n*=4) ± [se]{.smallcaps}. \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001 (Student\'s *t*-test). (B) Proteins from 1 ml aliquots of DC culture supernatants (or rhTSG-6 as control) were fractionated on SDS-PAGE, and TSG-6 was detected on Western blots using biotinylated R-C21 antibody. Samples shown are 50 ng rhTSG-6 and supernatants from untreated DC (control) and cells treated with LPS (10 ng/ml), IL-10 (20 ng/ml), LPS + IL-10, IFN-γ (5000 U/ml), or LPS + IFN-γ. Free TSG-6 (∼35 kDa) and TSG-6 • HC complexes (∼120 kDa) are detectable in the LPS-treated samples. (C) TSG-6 and (D) PTX3 were detected in PMN culture supernatants (5×10^6^ cells/ml) by sandwich ELISA at 30 min, 4 h, and 20 h after LPS stimulation (100 ng/ml). TSG-6 and PTX3 values are plotted as ng/ml (*n*=4) ± [se]{.smallcaps}. Data for one donor out of five tested are shown.](zgb0070948670004){#F4}

As shown in [Figure 4](#F4){ref-type="fig"}, C and D, which illustrates the results for one out of five donors tested, TSG-6 as well as PTX3 are released by PMN upon engagement of TLR4 by LPS. The kinetics of TSG-6 release is in agreement with transcription data and with experiments performed in the presence of actinomycin D (not shown), which suggest degranulation followed by de novo transcription. As reported previously \[[@B2]\], the time scale of the PTX3 increase in the supernatant indicates rapid release and absence of transcription.

Localization of TSG-6 in neutrophils
------------------------------------

PTX3 is stored in neutrophil-specific granules \[[@B2]\]. Here, confocal microscopy was used to identify the localization of TSG-6 within freshly isolated and cultured neutrophils. The images shown in **[Figure 5](#F5){ref-type="fig"}A** point to the presence of TSG-6 in PMN granules of resting PMN, where it colocalizes partially with PTX3 in lactoferrin-positive PMN granules, i.e., specific granules. Thirty minutes after LPS treatment, TSG-6 and PTX3 staining in granules was reduced, suggesting release by degranulation ([Fig. 5](#F5){ref-type="fig"}B). After 4 h, immunoreactivity for TSG-6 in granules had disappeared but was now present in the cytoplasm, localized in vesicular structures ([Fig. 5](#F5){ref-type="fig"}B). In contrast, no immunoreactivity for PTX3 was observed at this time-point after LPS treatment. These results are in agreement with the mRNA studies described above, which indicated LPS-induced *TSG-6* transcription; on the other hand, *PTX3* mRNA is expressed only at the promyelocytic stage, where the protein is stored in granules and released upon TLR engagement \[[@B2]\].

![Localization of TSG-6 and PTX3 within neutrophil granules.\
Neutrophils were freshly isolated (A) or cultured in the presence of 100 ng/ml LPS for 30 min or 4 h (B). Cells were fixed and stained for hTSG-6 (green), PTX3 (red), or lactoferrin (red; see Materials and Methods). Nuclei were stained with Hoechst 33258. A representative cell is shown in each panel. Specific granules were identified as lactoferrin positive.](zgb0070948670005){#F5}

Immunohistochemistry
--------------------

To assess PTX3 and TSG-6 localization in inflamed tissues in vivo, their expression was analyzed by immunohistochemistry in biopsies of colon mucosa from patients with inflammatory bowel disease. As shown in **[Figure 6](#F6){ref-type="fig"}**, a huge inflammatory infiltrate, involving the mucosa and the superficial layers of the submucosa, is associated with detachment and distortion of the crypts. PTX3 expression ([Fig. 6](#F6){ref-type="fig"}A) is observed in the inflammatory cells of the lamina propria and also beneath the surface mucosa and in the perivascular spaces, with an interstitial and extracellular pattern of distribution. TSG-6 staining ([Fig. 6](#F6){ref-type="fig"}E) is diffusely localized in the inflammatory infiltrate in the mucosa and submucosa. PTX3 and TSG-6 were observed in the cytoplasm of macrophages ([Fig. 6](#F6){ref-type="fig"}, B and F), granulocytes ([Fig. 6](#F6){ref-type="fig"}, C and G), and in some endothelial cells of the lamina propria ([Fig. 6](#F6){ref-type="fig"}, D and H). For both proteins, no immunostaining was observed in the absence of primary antibodies. Double immunofluorescence analysis indicated that there was TSG-6 protein expression in CD15^+^ neutrophils (**[Fig. 7](#F7){ref-type="fig"}A**), CD68^+^ macrophages ([Fig. 7](#F7){ref-type="fig"}B), and CD31^+^ endothelial cells ([Fig. 7](#F7){ref-type="fig"}C).

![PTX3 and TSG-6 are expressed at inflammatory sites in vivo.\
PTX3 (A--D) and TSG-6 (E--H) were determined by immunohistochemistry using 3′-diaminobenzidine tetrahydrochloride detection with hematoxylin counterstaining in colon mucosa from a patient with inflammatory bowel disease. (A) PTX3 expression in the inflammatory cells of the lamina propria, beneath the surface mucosa (\*\*) and in perivascular spaces (\*). (E) TSG-6 staining in the inflammatory infiltrate in the mucosa (M) and in the submucosa (SM). (B--D and F--H) Cellular localization of PTX3 and TSG-6 in the cytoplasm of macrophages (B and F), granulocytes (C and G, arrows), and in some endothelial cells of the lamina propria (D and H, arrows). No immunochemical signal was observed when the primary antibody was omitted. CC, Colonic crypts; NC, negative control. The original magnifications used are: ×4 (A and E), ×100 (B and F), and ×40 (C, D, G, and H).](zgb0070948670006){#F6}

![Cellular localization of PTX3 and TSG-6 by immunofluorescence.\
Double immunofluorescence analysis of TSG-6 expression by neutrophils (A), macrophages (B), and endothelial cells (C, arrows). TSG-6 is denoted in red and CD15, CD68, and CD31 in green. \*\*, Rare granulocytes (A) and macrophages (B) not producing TSG-6. The original magnification used is ×100.](zgb0070948670007){#F7}

These results suggest that PTX3 and TSG-6 are expressed in inflammatory conditions in vivo by leukocytes and endothelial cells.

DISCUSSION
==========

PTX3 is a multifunctional soluble pattern recognition receptor involved in inflammation and innate immunity \[[@B1]\]. Similarly, TSG-6, which has anti-inflammatory and chondroprotective effects, is produced in the context of inflammatory processes and diseases (reviewed in refs. \[[@B14], [@B15]\]). Both of these proteins are up-regulated specifically during cumulus oophorus expansion in response to hormonal ovulatory stimuli and oocyte soluble factors, such as the TGF-β family member growth differentiation factor-9 \[[@B21]\]. PTX3 and TSG-6 colocalize in the cumulus matrix and play a crucial role in cumulus expansion, where deficiency of either protein causes instability of the cumulus ECM as a result of defective hyaluronan incorporation and female infertility \[[@B19], [@B22]\]. The results reported here provide new insights into the expression of the TSG-6 and PTX3 genes in various cell types, including different leukocyte populations, in response to pro- and anti-inflammatory mediators and demonstrate the expression of both proteins in leukocytes and endothelial cells in inflammatory conditions.

In this study, we generally observed little or no basal expression of *TSG-6* or *PTX3* mRNA in any of the cell types analyzed, with the exception of *TSG-6* in neutrophils. However, both mRNAs were induced rapidly by proinflammatory stimuli, consistent with their involvement in inflammation and innate immune responses.

Our attention has been focused particularly on leukocytes, as although these cells are known to be a major source of PTX3, TSG-6 has not been studied extensively in this context \[[@B14]\]. *TSG-6* has emerged, in expression-profiling analyses, among the inflammation-inducible genes in leukocytes \[[@B52], [@B53]\], but to our knowledge, after the original description by Lee and colleagues \[[@B54]\], who observed *TSG-6* mRNA in PBMCs after treatment with TNF, Con A, or PHA, this is the first systematic analysis of TSG-6 expression and regulation in leukocyte subpopulations.

Mononuclear phagocytes responded to LPS engagement of TLR4 by rapidly producing *TSG-6* and *PTX3* in a dose-dependent manner. Thus, similarly to *PTX3*, *TSG-6* behaves as an immediate early gene in leukocytes. In particular, we observed high levels of *TSG-6* mRNA in monocytes, macrophages, and MoDC, which was rapidly detectable even upon stimulation with low levels of LPS, and this result was confirmed at the protein level, in vitro and in inflamed tissues. Freshly isolated PMN were the only cell type analyzed that had high basal levels of *TSG-6* mRNA expression; this was elevated following treatment with LPS but was lost after 20 h in culture without stimulation. In contrast, PMN incubated with LPS and/or IFN-γ maintained high levels of *TSG-6* mRNA after 20 h of culture.

*PTX3* mRNA is not detectable in mature PMN under any of the conditions analyzed, whereas it is produced by pro-myelocytes \[[@B2]\]; the protein is stored in neutrophil-specific granules and undergoes release in response to microbial recognition and inflammatory stimuli \[[@B2]\], resulting in pathogen recognition and clearance. Confocal analysis suggested that TSG-6 is also present in specific granules, where it partially colocalizes with PTX3, and both proteins are released upon LPS stimulation. Finally, immunohistochemistry demonstrated the coexpression of TSG-6 and PTX3 in leukocytes at inflammatory sites in vivo.

TSG-6 is an anti-inflammatory mediator, which inhibits neutrophil recruitment in different models of inflammation \[[@B36]--[@B38]\], an activity that is mediated by the Link module and might be a result of modulation of neutrophil adhesion to the endothelium. Interestingly, PTX3 has also been shown to have regulatory effects on inflammatory reactions \[[@B7], [@B55]\]. The rapid availability of PTX3 at the onset of inflammation could be important for the development of an appropriate innate immune response to invading pathogens, whereas the local expression of TSG-6 could serve to control neutrophil migration, thus preventing host tissue damage \[[@B35]\]. Furthermore, the combined actions of PTX3 and TSG-6 might support wound healing through the deposition of HA-rich ECM; this would be in line with the role suggested for neutrophils in tissue remodeling based on the transcriptional profiles seen in innate responses \[[@B56]\]. The secretion of TSG-6 protein by neutrophils is also of interest in relation to its recently reported role as an inhibitor of RANKL-mediated osteoclastic bone resorption \[[@B57]\]. RANKL is expressed by normal and inflammatory neutrophils, and its receptor (RANK) and also osteoprotegrin (a soluble inhibitor of RANKL) are expressed only by neutrophils exposed to inflammatory stimuli, e.g., in synovial fluids from patients with RA \[[@B58]\]. Therefore, TSG-6 can be added to the list of molecules expressed by neutrophils that modulate bone remodeling, where these cells may have an important role in the regulation of bone turnover at inflammatory sites \[[@B59]\].

In phagocytes, we observed that preincubation of cells with anti-inflammatory cytokines (IL-4 and IL-13) resulted in marked reductions in LPS-induced expression of *TSG-6* and *PTX3* mRNA. In contrast, pretreatment with IL-10 resulted in differential regulation of the two genes, where IL-10 acted synergistically with LPS in stimulating *PTX3* expression \[[@B40], [@B48]\] but inhibited the induction of *TSG-6*. PTX3 acts at an early stage in the immune response (i.e., before production of antibodies), being induced as a result of the recognition of pathogens and promoting complement activation and phagocytosis (as a result of opsonization). Thus, IL-10 contributes to the activation of the humoral arms of the innate and adaptive immune responses via PTX3 and antibodies, respectively \[[@B40], [@B60]\]. Moreover, IL-10 is involved in chronic inflammation and in the resolution of inflammatory activity \[[@B60]\] as well as playing a role in tissue remodeling by modulating the expression of genes involved in the synthesis and breakdown of ECM in connective tissue \[[@B60]\]. Given that PTX3 and TSG-6 are involved in the assembly of HA-rich matrices, the divergent effects of IL-10 in modulating their expression suggest that these two proteins might have distinct roles in tissue remodeling during chronic inflammation.

The in vitro and ex vivo results reported here suggest that mononuclear phagocytes, DC, and neutrophils may be important sources of TSG-6 at sites of inflammation, where this protein is understood to participate in the regulation of leukocyte recruitment and in tissue repair and remodeling.
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